Jeannette van der Giessen

Suggest Changes
Learn More
BACKGROUND Outcomes remain poor for children after relapse of acute lymphoblastic leukemia (ALL), especially after early marrow relapse. Bortezomib is a proteasome inhibitor with in vitro synergy(More)
  • 1